Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 12.75
- Piotroski Score 5.00
- Grade Buy
- Symbol (VCEL)
- Company Vericel Corporation
- Price $59.09
- Changes Percentage (4.19%)
- Change $2.38
- Day Low $56.52
- Day High $60.16
- Year High $60.16
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $57.00
- High Stock Price Target $60.00
- Low Stock Price Target $55.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.01
- Trailing P/E Ratio 4438
- Forward P/E Ratio 4438
- P/E Growth 4438
- Net Income $-3,182,000
Income Statement
Quarterly
Annual
Latest News of VCEL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Vericel Corp (VCEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic FDA ...
Nexobrid is expected to drive growth in 2025, with Macy Arthro contributing modestly. Macy's 20% growth is sustained by strong indicators. Early Arthro cases show promise for new adoption and increase...
By Yahoo! Finance | 2 weeks ago -
Vericel Corp. (VCEL) Cooled Down in Q3 After a 20% Rise in the First Half
Conestoga Capital Advisors reported on the third-quarter 2024 performance and mentioned Vericel Corporation as a notable stock. Despite its positive performance, the company is not among the most popu...
By Yahoo! Finance | 1 month ago -
Vericel Corporation (NASDAQ:VCEL) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Vericel Corporation (NASDAQ:VCEL) recently reported a quarterly loss, causing shares to drop. Analysts predict a 12% revenue increase in 2024, with earnings expected to rise significantly. Despite a d...
By Yahoo! Finance | 3 months ago
